Continuing trends in U.S. brand-name and generic drug competition.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of medical economics"
DOI: 10.1080/13696998.2021.1952795
Abstract: OBJECTIVE To provide updated evidence in a series of analyses of U.S. trends over the past two decades in key financial metrics for branded drugs: market exclusivity periods (MEPs, the time between launch and first… read more here.
Keywords: nmes 250; generic entry; drug; brand ... See more keywords
Hormonal Therapy Drug Switching, Out-of-Pocket Costs, and Adherence among Older Women with Breast Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djac062
Abstract: BACKGROUND Adherence to aromatase inhibitors (AIs) and tamoxifen has significant survival benefits for postmenopausal women diagnosed with hormone receptor-positive (HR+) breast cancer. Reduced out-of-pocket (OOP) costs and treatment-related side effects could increase therapy adherence. Given… read more here.
Keywords: adherence; non lis; generic entry; breast cancer ... See more keywords
The Impact of Tiered-Pricing Framework on Generic Entry in Canada.
Sign Up to like & getrecommendations! Published in 2020 at "International journal of health policy and management"
DOI: 10.34172/ijhpm.2020.215
Abstract: BACKGROUND Generic drug prices have been capped at specified percentages of the interchangeable branded drug's price by the Canadian provincial public drug plans since 1993. The Pan-Canadian Pharmaceutical Alliance, formed as a coalition by the… read more here.
Keywords: generic entry; impact; tpf; drug ... See more keywords